Trade
Trading Type
Spot
Trade crypto freely
Alpha
Points
Get promising tokens in streamlined on-chain trading
Pre-Market
Trade new tokens before they are officially listed
Margin
Magnify your profit with leverage
Convert & Block Trading
0 Fees
Trade any size with no fees and no slippage
Leveraged Tokens
Get exposure to leveraged positions simply
Futures
Futures
Points
Hundreds of contracts settled in USDT or BTC
Options
HOT
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Earn
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
New
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
New
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-Stop Lending Hub
VIP Wealth Hub
New
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
BTC Staking
HOT
Stake BTC and earn 10% APR
GUSD Minting
New
Use USDT/USDC to mint GUSD for treasury-level yields
More
- Trending TopicsView More
25.62K Popularity
11.65K Popularity
22.47K Popularity
7.57K Popularity
90.24K Popularity
- Pin
- 🎃 Halloween is here! Four GDOGs line up! 👻
🧡 Can you spot which GDOG secretly dressed up for Halloween today?
💰 Join the fun — 3 lucky users will each win 20 USDT!
👉 How to participate:
1️⃣ Follow Gate_Square
2️⃣ Like this post
3️⃣ Comment with your answer
🗓️ Deadline: November 2, 2025, 16:00 UTC - 💥 Gate Square Event: #PostToWinPIGGY 💥
Post original content on Gate Square related to PIGGY or Launchpool for a chance to share 200 PIGGY rewards!
📅 Event Period: Oct 30, 2025, 10:00 – Nov 6, 2025, 16:00 (UTC)
📌 Related Campaign:
Launchpool 👉 https://www.gate.com/announcements/article/47886
📌 How to Participate:
1️⃣ Post original content related to PIGGY or the Launchpool campaign.
2️⃣ Content must be at least 80 words.
3️⃣ Add the hashtag #PostToWinPIGGY
4️⃣ Include a screenshot showing your participation in the Launchpool.
🏆 Rewards (Total: 200 PIGGY)
🥇 1st Prize (1 winners): 40 PI - 🚀 Gate Square Creator Certification Incentive Program Is Live!
Join Gate Square and share over $10,000 in monthly creator rewards!
Whether you’re an active Gate Square creator or an established voice on another platform, consistent quality content can earn you token rewards, exclusive Gate merch, and massive traffic exposure!
✅ Eligibility：
You can apply if you meet any of the following:
1️⃣ Verified creator on another platform
2️⃣ At least 1,000 followers on a single platform (no combined total)
3️⃣ Gate Square certified creator meeting follower and engagement criteria
Click to apply now 👉
Eli Lilly shares jumped 13% as the company released weight loss pills research data
On April 17, Eli Lilly (LLY.N) rose 13% pre-market, after releasing weight loss drug research data. Eli Lilly today announced positive Phase 3 topline results from ACHIEVE-1, evaluating the safety and efficacy of oglilam compared to placebo in adults with type 2 diabetes and inadequate control through diet and exercise alone. Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist with no dietary and water restrictions, successfully completing a Phase 3 trial. If approved, the company is confident in its ability to roll out Orforglipron globally without supply constraints. This will further Eli Lilly’s mission to reduce chronic diseases such as type 2 diabetes, which is expected to affect approximately 760 million adults by 2050.